» Articles » PMID: 36076929

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 9
PMID 36076929
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we demonstrated that the proton pump inhibitor, esomeprazole magnesium hydrate (MH), could have potential as a repurposed treatment against preeclampsia, a serious obstetric condition. In this study we investigate the difference in the preclinical effectiveness between 100 µM of esomeprazole MH and its hydration isomer, esomeprazole magnesium trihydrate (MTH). Here, we found that both treatments reduced secretion of sFLT-1 (anti-angiogenic factor) from primary cytotrophoblast, but only esomeprazole MH reduced sFLT-1 secretion from primary human umbilical vein endothelial cells (assessed via ELISA). Both drugs could mitigate expression of the endothelial dysfunction markers, vascular cell adhesion molecule-1 and endothelin-1 (via qPCR). Neither esomeprazole MH nor MTH quenched cytotrophoblast reactive oxygen species production in response to sodium azide (ROS assay). Finally, using wire myography, we demonstrated that both compounds were able to induce vasodilation of human omental arteries at 100 µM. Esomeprazole is safe to use in pregnancy and a candidate treatment for preeclampsia. Using primary human tissues and cells, we validated that esomeprazole is effective in enhancing vascular relaxation, and can reduce key factors associated with preeclampsia, including sFLT-1 and endothelial dysfunction. However, esomeprazole MH was more efficacious than esomeprazole MTH in our in vitro studies.

Citing Articles

The Pathophysiological, Genetic, and Hormonal Changes in Preeclampsia: A Systematic Review of the Molecular Mechanisms.

Chiang Y, Seow K, Chen K Int J Mol Sci. 2024; 25(8).

PMID: 38674114 PMC: 11050545. DOI: 10.3390/ijms25084532.


The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin.

Fato B, Beard S, Binder N, Pritchard N, Kaituu-Lino T, de Alwis N Biomedicines. 2023; 11(10).

PMID: 37893034 PMC: 10603897. DOI: 10.3390/biomedicines11102660.


Atypical Preeclampsia before 20 Weeks of Gestation-A Systematic Review.

Modzelewski J, Siarkowska I, Pajurek-Dudek J, Feduniw S, Muzyka-Placzynska K, Baran A Int J Mol Sci. 2023; 24(4).

PMID: 36835158 PMC: 9964444. DOI: 10.3390/ijms24043752.


Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort.

Kang H, Kim S, Kim J, Kim E, Choi H, Lim H Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36355557 PMC: 9694889. DOI: 10.3390/ph15111385.

References
1.
Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

2.
Austgulen R, Lien E, Vince G, Redman C . Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 1997; 71(1):53-8. DOI: 10.1016/s0301-2115(96)02647-4. View

3.
Kaituu-Lino T, Brownfoot F, Beard S, Cannon P, Hastie R, Nguyen T . Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. PLoS One. 2018; 13(2):e0188845. PMC: 5821305. DOI: 10.1371/journal.pone.0188845. View

4.
Cindrova-Davies T, Sanders D, Burton G, Charnock-Jones D . Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res. 2010; 89(3):671-9. PMC: 3028975. DOI: 10.1093/cvr/cvq346. View

5.
Binder N, Brownfoot F, Beard S, Cannon P, Nguyen T, Tong S . Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. Pregnancy Hypertens. 2020; 22:86-92. DOI: 10.1016/j.preghy.2020.07.013. View